A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Trial Profile

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs TG 01 Targovax (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Targovax
  • Most Recent Events

    • 02 Nov 2017 According to a Targovax media release, the second cohort of patients started recruitment in 2015 and the last patient enrolled has been in the trial for more than one year.
    • 02 Nov 2017 According to a Targovax media release, three year survival data expected in H1 2018. First cohort is of 19 patients and second cohort of this trial is of 13 patients.
    • 12 Oct 2017 One-year data from modified cohort presented in a Targovax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top